scispace - formally typeset
B

Bruno Silva-Santos

Researcher at Instituto de Medicina Molecular

Publications -  111
Citations -  8131

Bruno Silva-Santos is an academic researcher from Instituto de Medicina Molecular. The author has contributed to research in topics: T cell & Cytotoxic T cell. The author has an hindex of 43, co-authored 106 publications receiving 6085 citations. Previous affiliations of Bruno Silva-Santos include King's College London & University of Lisbon.

Papers
More filters
Journal ArticleDOI

Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

Andrea Cossarizza, +462 more
- 01 Oct 2019 - 
TL;DR: These guidelines are a consensus work of a considerable number of members of the immunology and flow cytometry community providing the theory and key practical aspects offlow cytometry enabling immunologists to avoid the common errors that often undermine immunological data.
Journal ArticleDOI

CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets.

Julie C. Ribot, +13 more
- 08 Mar 2009 - 
TL;DR: The cytokine profiles of peripheral γδ T cells are predetermined mainly by a mechanism involving CD27, and these phenotypes were established during thymic development.
Journal ArticleDOI

γδ T cells in cancer.

Bruno Silva-Santos, +2 more
- 01 Nov 2015 - 
TL;DR: The current knowledge from both human and mouse studies are integrated to highlight the potential of γδ T cell modulation to improve cancer immunotherapy.
Journal ArticleDOI

Classification of current anticancer immunotherapies

Lorenzo Galluzzi, +98 more
- 30 Dec 2014 - 
TL;DR: A critical, integrated classification of anticancer immunotherapies is proposed and the clinical relevance of these approaches is discussed.
Journal ArticleDOI

Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies

Zsolt Sebestyén, +4 more
- 01 Mar 2020 - 
TL;DR: The challenges and opportunities for the clinical implementation of cancer immunotherapies based on γδT cells and their receptors are discussed, which display potent cytotoxicity towards a large array of haematological and solid tumours while preserving normal tissues.